<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717636</url>
  </required_header>
  <id_info>
    <org_study_id>PSInCor-ICxHospDia</org_study_id>
    <nct_id>NCT03717636</nct_id>
  </id_info>
  <brief_title>Early or Non-revoked in Hospital-day in Patients With Acute Heart Failure</brief_title>
  <acronym>HospDia</acronym>
  <official_title>Prospective and Randomized Comparative Analysis, Between Early or Non-revoked in Day Hospital in Patients With Acute Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure is one of the major causes of hospitalization in Brazil and worldwide. Recent&#xD;
      studies attempt to identify readmission and prognostic markers at the time of discharge from&#xD;
      these patients. The reassessment and possibility of early therapeutic adjustment may be&#xD;
      relevant in this context. Therefore, the prospective and randomized comparative use of early&#xD;
      re-evaluation in Hospital-day versus non-intervention group has not yet been described. The&#xD;
      objective of this study was to evaluate the impact on the re-hospitalization rate in 30 days&#xD;
      of the early re-evaluation of the patients in the day-hospital versus the non-intervention&#xD;
      group in heart failure. For this, a unicentric, randomized and prospective study will be&#xD;
      performed, in which the Hospital-Day strategy is performed versus no intervention in a&#xD;
      comparative manner. Hospital data (test results, medical outcomes, complications) of patients&#xD;
      will be analyzed for safety and effectiveness. The hypothesis of this study is that the&#xD;
      Hospital-Day strategy is superior to the non-intervention strategy and causes fewer&#xD;
      rehospitalizations within 30 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of 30-days rehospitalization rate</measure>
    <time_frame>30 days</time_frame>
    <description>30-days rehospitalization rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>30-days mortality rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Heart Failure</condition>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Hospital Day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the Hospital-Day group will return for medical evaluation 7-14 days in the specific unit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Outpatient clinic</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients in control group will return for medical evaluation 30 days at the outpatient clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical evaluation</intervention_name>
    <description>return of medical evaluation after discharge</description>
    <arm_group_label>Hospital Day</arm_group_label>
    <arm_group_label>Outpatient clinic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult men and women aged&gt; 18 years.&#xD;
&#xD;
          -  Presence of decomposed CF III or IV of NYHA characterized by&gt; 1 symptom (dyspnea,&#xD;
             orthopnea or edema) + 1 clinical sign (rales, edema, ascites or pulmonary congestion&#xD;
             on chest X-ray).&#xD;
&#xD;
          -  LVEF &lt;45% on transthoracic echocardiography.&#xD;
&#xD;
          -  BNP&gt; 400 pg / mL.&#xD;
&#xD;
          -  Clinical condition of hospital discharge.&#xD;
&#xD;
          -  Signed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Body mass index greater than 40 kg / m2.&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease.&#xD;
&#xD;
          -  Acute coronary syndrome.&#xD;
&#xD;
          -  Acute myocarditis.&#xD;
&#xD;
          -  Valvular heart disease.&#xD;
&#xD;
          -  Need to use vasoactive drug.&#xD;
&#xD;
          -  Cirrhosis of the liver Child C.&#xD;
&#xD;
          -  Chronic dialysis renal insufficiency or creatinine&gt; 3.0 mg / dL.&#xD;
&#xD;
          -  Indication of implantation device of artificial stimulation.&#xD;
&#xD;
          -  Pulmonary thromboembolism.&#xD;
&#xD;
          -  Neoplasm terminal.&#xD;
&#xD;
          -  Sepsis or septic shock.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mucio Tavares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unidade Clínica de Emergência</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandre Soeiro, MD</last_name>
    <phone>+55112661-5299</phone>
    <email>alexandre.soeiro@bol.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Instituto do Coração - HMFMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Soeiro, MD</last_name>
      <phone>5511-2661-5299</phone>
      <email>alexandre.soeiro@bol.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

